J&J’s challenge to AstraZeneca in lung cancer takes flight with PhIII PFS win

Johnson & Johnson said that its combination treatment staved off cancer progression for longer than AstraZeneca’s blockbuster Tagrisso as a first option for patients with a form of advanced lung cancer.

In the Phase III MARIPOSA study, J&J pitted its bispecific antibody Rybrevant and tyrosine kinase inhibitor lazertinib against Tagrisso alone. The study included 1,074 patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Kevin Colley on Career Ending Injury and His Path to Recovery Through Psychedelic-Therapy | Psychedelic Spotlight

Kevin Colley, a former professional hockey player with over a decade of experience, including a stint with the NHL’s New York Islanders, embarked on a

October 5, 2023

Employers Press Congress to Cement Health Price Transparency Before Trump’s Return

It seems simple: Require hospitals and insurers to post their negotiated prices for most healthcare services and — bingo — competition follows, yielding lower costs

December 21, 2024

SPAC merger falls through between Wilbur Ross’ blank check company and Alzheimer’s player

Cambridge, MA-based Aprinoia Therapeutics and a blank check company helmed by former US Commerce Secretary Wilbur Ross have called off their proposed merger. Under the

August 25, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.